Barclays PLC Amicus Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 631,705 shares of FOLD stock, worth $6.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

631,705

Previous 631,705 -0.0%

Holding current value

$6.18 Million

Previous $6.75 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$9.55 - $12.09 $1.77 Million - $2.24 Million	185,314 Added 41.51%	631,705 $6.75 Million
Q2 2024 Aug 14, 2024	BUY	$9.04 - $11.75 $880,984 - $1.15 Million	97,454 Added 27.93%	446,391 $4.43 Million
Q1 2024 May 15, 2024	SELL	$11.43 - $14.24 $4.33 Million - $5.39 Million	-378,838 Reduced 52.05%	348,937 $4.11 Million
Q4 2023 Feb 15, 2024	BUY	$9.97 - $14.52 $3.14 Million - $4.58 Million	315,339 Added 76.46%	727,775 $10.3 Million
Q3 2023 Nov 07, 2023	BUY	$11.78 - $13.86 $83,590 - $98,350	7,096 Added 1.75%	412,436 $5.02 Million
Q2 2023 Aug 03, 2023	SELL	$10.72 - $13.3 $555,403 - $689,073	-51,810 Reduced 11.33%	405,340 $5.09 Million
Q1 2023 May 04, 2023	BUY	$10.91 - $13.54 $385,450 - $478,368	35,330 Added 8.38%	457,150 $5.07 Million
Q4 2022 Feb 13, 2023	BUY	$9.89 - $12.7 $161,197 - $206,997	16,299 Added 4.02%	421,820 $5.15 Million
Q3 2022 Nov 03, 2022	BUY	$9.82 - $12.75 $3.8 Million - $4.94 Million	387,185 Added 2111.61%	405,521 $4.23 Million
Q2 2022 Aug 12, 2022	SELL	$6.23 - $11.12 $553,734 - $988,367	-88,882 Reduced 82.9%	18,336 $197,000
Q1 2022 May 16, 2022	SELL	$7.89 - $12.48 $1.73 Million - $2.73 Million	-219,041 Reduced 67.14%	107,218 $1.02 Million
Q4 2021 Feb 14, 2022	SELL	$9.82 - $12.44 $1.24 Million - $1.57 Million	-125,879 Reduced 27.84%	326,259 $3.77 Million
Q3 2021 Nov 09, 2021	BUY	$8.74 - $11.84 $2 Million - $2.7 Million	228,331 Added 102.02%	452,138 $4.32 Million
Q2 2021 Aug 13, 2021	SELL	$8.71 - $10.72 $1.81 Million - $2.23 Million	-207,946 Reduced 48.16%	223,807 $2.16 Million
Q1 2021 May 13, 2021	BUY	$9.2 - $23.86 $2.11 Million - $5.48 Million	229,812 Added 113.8%	431,753 $4.27 Million
Q4 2020 Feb 11, 2021	SELL	$13.47 - $24.89 $3.22 Million - $5.94 Million	-238,687 Reduced 54.17%	201,941 $4.66 Million
Q3 2020 Nov 12, 2020	SELL	$12.89 - $15.89 $499,577 - $615,848	-38,757 Reduced 8.08%	440,628 $6.22 Million
Q2 2020 Aug 12, 2020	SELL	$8.86 - $15.69 $726,130 - $1.29 Million	-81,956 Reduced 14.6%	479,385 $7.23 Million
Q1 2020 May 13, 2020	SELL	$6.63 - $11.16 $1.08 Million - $1.81 Million	-162,566 Reduced 22.46%	561,341 $5.19 Million
Q4 2019 Feb 10, 2020	BUY	$7.48 - $10.75 $3.72 Million - $5.34 Million	497,092 Added 219.16%	723,907 $7.05 Million
Q3 2019 Nov 14, 2019	BUY	$8.02 - $13.25 $621,686 - $1.03 Million	77,517 Added 51.92%	226,815 $1.82 Million
Q2 2019 Aug 14, 2019	BUY	$10.96 - $14.4 $719,096 - $944,798	65,611 Added 78.4%	149,298 $1.86 Million
Q1 2019 May 15, 2019	BUY	$10.04 - $13.92 $595,783 - $826,026	59,341 Added 243.74%	83,687 $1.14 Million
Q4 2018 Feb 14, 2019	SELL	$8.38 - $13.44 $631,583 - $1.01 Million	-75,368 Reduced 75.58%	24,346 $233,000
Q3 2018 Nov 14, 2018	BUY	$11.6 - $16.54 $995,906 - $1.42 Million	85,854 Added 619.44%	99,714 $1.21 Million
Q2 2018 Aug 14, 2018	SELL	$13.13 - $17.09 $423,849 - $551,682	-32,281 Reduced 69.96%	13,860 $216,000
Q1 2018 May 15, 2018	BUY	$13.76 - $17.12 $194,497 - $241,991	14,135 Added 44.16%	46,141 $693,000
Q4 2017 Feb 14, 2018	BUY	$12.51 - $16.24 $352,456 - $457,545	28,174 Added 735.23%	32,006 $460,000
Q3 2017 Nov 14, 2017	BUY	$11.74 - $15.78 $44,987 - $60,468	3,832	3,832 $58,000

Others Institutions Holding FOLD

# of Institutions

312

Shares Held

314M

Call Options Held

516K

Put Options Held

833K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.75B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account